iRhythm Holdings,Inc. IRTC recently announced that it will acquire Vital Connect, Inc., a leader in wearable biosensor technology and ambulatory cardiac monitoring. The transaction is expected to expand iRhythm’s addressable market and accelerate its evolution from ambulatory cardiac monitoring into a broader cardiac monitoring and intelligence platform spanning ambulatory, inpatient and hospital-to-home care.
Per management, the acquisition marks an important milestone in iRhythm’s transition from ambulatory cardiac monitoring to a broader cardiac monitoring and intelligence platform. The addition of VitalConnect’s mobile cardiac telemetry (MCT), multi-vitals and hospital monitoring capabilities complements the Zio platform, expands the company’s patient and customer reach, and creates opportunities to accelerate growth, strengthen customer relationships and serve patients across a wider continuum of care.
Likely Trend of IRTC Stock Following the News
Shares of IRTC have lost 4% since the announcement on Aug. 6. Year to date, shares of the company have declined 30.6% against the industry’s 4.4% growth and the S&P 500’s 13.6% gain.
In the long run, the acquisition of VitalConnect could strengthen iRhythm’s growth prospects by broadening its cardiac monitoring portfolio and expanding its reach across different care settings. The combination of VitalConnect’s monitoring technologies with iRhythm’s established Zio platform and commercial infrastructure could create new revenue opportunities, strengthen relationships with healthcare providers and support wider adoption. The expanded portfolio also positions iRhythm to capture demand across ambulatory, inpatient and remote care markets, supporting its transition toward a more comprehensive cardiac monitoring platform.
IRTC currently has a market capitalization of $4.13 billion.
Image Source: Zacks Investment Research
More on the News
The acquisition broadens iRhythm’s cardiac monitoring capabilities by adding VitalConnect’s FDA-cleared platform, which supports multiple monitoring modalities, including MCT, as well as multi-vitals monitoring. VitalConnect offers capabilities including up to 30-day patient monitoring, four-in-one functionality, flexible service models and live look-in.
Together with Zio AT and iRhythm’s planned next-generation MCT offering, the combined portfolio is expected to provide clinicians with greater flexibility across different workflows and care settings. VitalConnect’s biosensor platform can monitor up to 11 physiological parameters, extending iRhythm’s reach into inpatient monitoring, remote patient monitoring and hospital-to-home care.
The transaction also combines complementary technology and expertise. VitalConnect contributes wearable biosensors, AI-enabled algorithms and cloud-based workflows, while iRhythm brings cardiac diagnostic expertise, clinical operations, proprietary algorithms and a scaled commercial platform. The integration could support faster product innovation and enable comprehensive solutions for health systems.
Financial Outlook of Acquisition
iRhythm will acquire VitalConnect for approximately $287.5 million, comprising $237.5 million in cash and approximately $50 million in iRhythm common stock. The company will provide up to $30 million in interim working capital financing to support VitalConnect’s operations before closing. The acquisition is anticipated to close by the end of 2026 and expected to be accretive to iRhythm’s revenue growth rate beginning in 2027.
Industry Prospects Favoring the Market
Going by the data provided by Mordor Intelligence, the cardiac monitoring market is predicted to be valued at $29.1 billion in 2026 and is expected to witness a CAGR of 5.04% through 2035.
Factors like the rising prevalence of cardiovascular diseases, growing geriatric population, technological advances in wireless & wearable devices, expansion of AI-enabled predictive analytics, reimbursement shift to ambulatory continuous monitoring, as well as increasing awareness and screening programs for heart health, are boosting the market’s growth.
Other News
iRhythm recently delivered strong second-quarter 2026 results with solid earnings and revenue growth. The quarter reflected broad-based commercial momentum across cardiology, primary care, innovative channels and international markets. Innovative channels were the fastest-growing area, supported by value-based care, primary care and population health partnerships.
The company secured FDA clearance for its third-generation algorithm, expected to reduce technician review time by up to 50% and generate approximately $100 million in cumulative savings over five years. iRhythm is also advancing predictive arrhythmia solutions and expanding its Zio platform.
iRhythm Holdings, Inc. Price
iRhythm Holdings, Inc. price | iRhythm Holdings, Inc. Quote
IRTC’s Zacks Rank & Key Picks
IRTC currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical GMED, West Pharmaceutical WST and The Cooper Companies COO.
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
iRhythm Holdings, Inc. (IRTC): Free Stock Analysis Report
The Cooper Companies, Inc. (COO): Free Stock Analysis Report
West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report
Globus Medical, Inc. (GMED): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).